Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 144
Filtrar
Mais filtros

Intervalo de ano de publicação
1.
J Clin Invest ; 134(6)2024 Jan 25.
Artigo em Inglês | MEDLINE | ID: mdl-38271117

RESUMO

BACKGROUNDThe tumor immune microenvironment can provide prognostic and therapeutic information. We aimed to develop noninvasive imaging biomarkers from computed tomography (CT) for comprehensive evaluation of immune context and investigate their associations with prognosis and immunotherapy response in gastric cancer (GC).METHODSThis study involved 2,600 patients with GC from 9 independent cohorts. We developed and validated 2 CT imaging biomarkers (lymphoid radiomics score [LRS] and myeloid radiomics score [MRS]) for evaluating the IHC-derived lymphoid and myeloid immune context respectively, and integrated them into a combined imaging biomarker [LRS/MRS: low(-) or high(+)] with 4 radiomics immune subtypes: 1 (-/-), 2 (+/-), 3 (-/+), and 4 (+/+). We further evaluated the imaging biomarkers' predictive values on prognosis and immunotherapy response.RESULTSThe developed imaging biomarkers (LRS and MRS) had a high accuracy in predicting lymphoid (AUC range: 0.765-0.773) and myeloid (AUC range: 0.736-0.750) immune context. Further, similar to the IHC-derived immune context, 2 imaging biomarkers (HR range: 0.240-0.761 for LRS; 1.301-4.012 for MRS) and the combined biomarker were independent predictors for disease-free and overall survival in the training and all validation cohorts (all P < 0.05). Additionally, patients with high LRS or low MRS may benefit more from immunotherapy (P < 0.001). Further, a highly heterogeneous outcome on objective response ​rate was observed in 4 imaging subtypes: 1 (-/-) with 27.3%, 2 (+/-) with 53.3%, 3 (-/+) with 10.2%, and 4 (+/+) with 30.0% (P < 0.0001).CONCLUSIONThe noninvasive imaging biomarkers could accurately evaluate the immune context and provide information regarding prognosis and immunotherapy for GC.


Assuntos
Neoplasias Gástricas , Humanos , Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/terapia , Radiômica , Imunoterapia , Tomografia Computadorizada por Raios X , Microambiente Tumoral , Biomarcadores , Prognóstico
2.
Am Surg ; 90(6): 1268-1278, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38225880

RESUMO

Across the nation, patients with locally advanced gastric cancer (LAGC) are managed with modalities including upfront surgery (US) and perioperative chemotherapy (PCT). Preoperative therapies have demonstrated survival benefits over US and thus long-term outcomes are expected to vary between the options. However, as these 2 modalities continue to be regularly employed, we sought to perform a decision analysis comparing the costs and quality-of-life associated with the treatment of patients with LAGC to identify the most cost-effective option. We designed a decision tree model to investigate the survival and costs associated with the most commonly utilized management modalities for LAGC in the United States: US and PCT. The tree described costs and treatment strategies over a 6-month time horizon. Costs were derived from 2022 Medicare reimbursement rates using the third-party payer perspective for physicians and hospitals. Effectiveness was represented using quality-adjusted life-years (QALYs). One-way, two-way, and probabilistic sensitivity analyses were utilized to test the robustness of our findings. PCT was the most cost-effective treatment modality for patients with LAGC over US with a cost of $40,792.16 yielding 3.11 QALYs. US has a cost of $55,575.57 while yielding 3.15 QALYs; the incremental cost-effectiveness ratio (ICER) was $369,585.25. One-way and two-way sensitivity analyses favored PCT in all variations of variables across their standard deviations. Across 100,000 Monte Carlo simulations, 100% of trials favored PCT. In our model simulating patients with LAGC, the most cost-effective treatment strategy was PCT. While US demonstrated improved QALYs over PCT, the associated cost was too great to justify its use.


Assuntos
Análise Custo-Benefício , Árvores de Decisões , Anos de Vida Ajustados por Qualidade de Vida , Neoplasias Gástricas , Humanos , Neoplasias Gástricas/terapia , Neoplasias Gástricas/economia , Neoplasias Gástricas/patologia , Estados Unidos , Qualidade de Vida , Gastrectomia/economia , Técnicas de Apoio para a Decisão , Análise de Custo-Efetividade
3.
Zhonghua Yi Xue Za Zhi ; 103(36): 2837-2849, 2023 Sep 26.
Artigo em Chinês | MEDLINE | ID: mdl-37726990

RESUMO

The disease burden of gastric cancer is considerable heavy in China, where the annual number of new gastric cancer cases and deaths rank first in the world. It has been shown that risk assessment, screening, and reducing risk factors may effectively reduce gastric cancer development in general population. However, there is currently a lack of practice guidelines on risk management of gastric cancer for the general public in China. This guideline was conducted by the Chinese Gastric Cancer Association (CGCA) and Chinese Society of Upper Gastrointestinal Surgeons (CSUGS). Based on the best research evidence and health expertise, we developed 17 questions and formulated 18 recommendations. These recommendations provide comprehensive guidance for the management of gastric cancer risk in the general public, with the potential to reduce the cancer development and the burden of disease.


Assuntos
Neoplasias Gástricas , Humanos , Medição de Risco , Gestão de Riscos , Neoplasias Gástricas/terapia
4.
Wiad Lek ; 76(5 pt 1): 956-963, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37326076

RESUMO

OBJECTIVE: The aim: To identify the main problems in the quality of life of patients with gastric cancer to optimize health care for them. PATIENTS AND METHODS: Materials and methods: The sociological study was performed by surveying 404 patients with gastric cancer usage questionnaires EORTC QLQ-C30 and QLQ-STO22. Calculations were performed according to the EORTC QLQ-C30 Scoring Manual and QLQ-STO22. The analysis of three main indicators was performed: functional scale, symptom scale and quality of life scale. RESULTS: Results: The quality of life of gastric cancer patients amounted to 51.80±11.35 on a 100-point scale. According to the QLQ-C30 functional scale, the psy¬cho-emotional sphere (59.62±12.91), social functioning (66.42±13.48) are the most impressive in patients. According to the results obtained in the QLQ-C30 symptoms scale, gastric cancer patients were most concerned about financial difficulties (57.18±12.45) and fatigue with a score of 50.12±10.86 on a 100-point scale. According to the QLQ-STO22 symptom scale in the study of patients, anxiety (59.07±12.46) and hair loss (56.97±11.78) amounted to the highest scores. CONCLUSION: Conclusions: Given the low quality of life of gastric cancer patients, they need psychological support, which is aimed at adapting to the manifestations of the disease and should be a mandatory component in the development of models or strategies for providing medical care to cancer patients. Standardized psychological care should be organized at all stages of diagnosis, treatment and rehabilitation in all institutions that provide treatment to gastric cancer pa¬tients. It is also important to develop and implement a comprehensive program to support gastric cancer patients in interaction with society, family and work.


Assuntos
Qualidade de Vida , Neoplasias Gástricas , Humanos , Qualidade de Vida/psicologia , Neoplasias Gástricas/psicologia , Neoplasias Gástricas/terapia , Ucrânia , Inquéritos e Questionários , Ansiedade/etiologia
5.
Future Oncol ; 19(8): 575-586, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37082938

RESUMO

Aim: To describe treatment patterns, healthcare resource utilization and costs in HER2-negative gastric/gastroesophageal (G/GEJ) cancer in the USA. Methods: Retrospective IQVIA Adjudicated Closed Claims database analysis; patients with HER2-negative G/GEJ cancer initiating systemic therapy between October 2016 and December 2019 were identified. Results: Among 1317 patients, platinum plus taxane regimens (54%) were common in neoadjuvant/adjuvant settings. Platinum-taxane (41%) and platinum-fluoropyrimidine (36%) regimens were common first-line therapies in the metastatic setting. Treatment regimens were heterogeneous in later lines. Hospitalization rates ranged from 39% (first-, second-line metastatic settings) to 61% (neoadjuvant/adjuvant setting). High healthcare resource utilization was driven by high outpatient costs. Mean per-patient per-month outpatient costs combining physician office and hospital visits ranged from US$10,944 to $12,582 (representing 52-70% of total costs). Conclusion: For G/GEJ cancer, systemic regimens varied across lines of therapy with variation increasing with subsequent therapy lines; high healthcare costs persist for systemic treatment, particularly outpatient services.


Assuntos
Platina , Neoplasias Gástricas , Humanos , Atenção à Saúde , Junção Esofagogástrica , Custos de Cuidados de Saúde , Estudos Retrospectivos , Neoplasias Gástricas/terapia
6.
BMC Health Serv Res ; 22(1): 1566, 2022 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-36544140

RESUMO

BACKGROUND: We aimed to investigate the association between fragmented cancer care in the early phase after cancer diagnosis and patient outcomes using national insurance claim data. METHODS: From a nationwide sampled cohort database, we identified National Health Insurance beneficiaries diagnosed with gastric cancer (ICD-10: C16) in South Korea during 2005-2013. We analyzed the results of a multiple logistic regression analysis using the generalized estimated equation model to investigate which patient and institution characteristics affected fragmented cancer care during the first year after diagnosis. Then, survival analysis using the Cox proportional hazard model was conducted to investigate the association between fragmented cancer care and five-year mortality. RESULTS: Of 2879 gastric cancer patients, 11.9% received fragmented cancer care by changing their most visited medical institution during the first year after diagnosis. We found that patients with fragmented cancer care had a higher risk of five-year mortality (HR: 1.310, 95% CI: 1.023-1.677). This association was evident among patients who only received chemotherapy or radiotherapy (HR: 1.633, 95% CI: 1.005-2.654). CONCLUSIONS: Fragmented cancer care was associated with increased risk of five-year mortality. Additionally, changes in the most visited medical institution occurred more frequently in either patients with severe conditions or patients who mainly visited smaller medical institutions. Further study is warranted to confirm these findings and examine a causal relationship between fragmented cancer care and survival.


Assuntos
Seguro , Neoplasias Gástricas , Humanos , Neoplasias Gástricas/terapia , Estudos Retrospectivos , Análise de Sobrevida , Modelos de Riscos Proporcionais
7.
Medicine (Baltimore) ; 101(43): e31341, 2022 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-36316866

RESUMO

The aim was to illuminate the difference in incidence, mortality, and disability-adjusted life-years (DALYs) of gastric cancer (GC) between the United States of America (US) and China. The multiple management was analyzed with stratification to explore an effective survival improvement strategy. The Global Burden of Disease Study data was analyzed to assess GC morbidity, mortality and DALYs from 1990 to 2019 in the US and China. The age-period-cohort model was established to generate estimation of metrics. Verification was completed and stratified analysis of the multiple management was performed by accessing data of Surveillance, Epidemiology, and End Results database in 1992 to 2019. Continuous downtrends in GC incidence, mortality and DALYs from 1990 to 2019 and persistent uptrends in 1-, 3-year survival from 1992 to 2019 were observed in the US population. In the Chinese population, the overall trends of incidence, mortality and DALYs decreased with a fluctuating manner. The lower overall survival rates were observed in elderly, unmarried patients, distant disease and poor grade, as well as patients lacking of medical treatment (P < .05). In stratified analyses, single local therapy decreased and the other modalities increased over time across different stages. Moreover, combined treatment and single systemic therapy decreased, but single local and conservative therapy increased with age. The study quantified the incidence, GC-specific mortality and DALYs in the US and China and estimated stage profiles, 1- and 3-year survival in the US. The heavy burden on later-onset GC (>70) and potential increase on early-onset GC (<40) needed to be addressed. Combined modalities and single chemotherapy were becoming more widely used over time, however, their uses decreased with age because of poor physical fitness. Our findings provide new insights into management tailoring appropriately to specific subgroups contributes to the increasing survival rate.


Assuntos
Neoplasias Gástricas , Humanos , Idoso , Incidência , Anos de Vida Ajustados por Qualidade de Vida , Neoplasias Gástricas/epidemiologia , Neoplasias Gástricas/terapia , Morbidade , Doença Crônica
8.
Curr Oncol ; 29(7): 4923-4935, 2022 07 12.
Artigo em Inglês | MEDLINE | ID: mdl-35877251

RESUMO

BACKGROUND: Gastric cancer is a prevalent cause of tumor death. Tumor immunotherapy aims to reshape the specific immunity to tumors in order to kill the tumor. LncRNAs play a pivotal role in regulating the tumor immune microenvironment. Herein, immune-related lncRNAs were used to establish a prognosis risk-assessment model for gastric cancer and provide personalized predictions while providing insights and targets for gastric cancer treatment to enhance patient prognosis. METHODS: Gastric adenocarcinoma transcriptome and clinical data were acquired from the The Cancer Genome Atlas (TCGA) database to screen the immune-related lncRNAs. Then, LASSO COX regression was utilized to construct the prognosis risk-assessment model. Afterward, the reliability of the model was evaluated the relationship between immune infiltration, clinical characteristics, and the model was analyzed. RESULTS: We identified 13 lncRNAs and constructed the prognosis assessment model. According to the median risk score of the training set, the patients were assigned to different risk groups. Overall survival time was shorter in the high-risk group. In the high-risk group, higher infiltration of mono-macrophages, dendritic cells, CD4+ T cells, and CD8+ T cells was observed. Moreover, the model was positively related to tumor metastasis. CONCLUSION: The prognosis risk-assessment model developed in this research can effectively predict the prognosis of gastric cancer patients. This tool is expected to be further applied to clinics in the future, thus providing a novel target for immunotherapy in gastric cancer patients.


Assuntos
RNA Longo não Codificante , Neoplasias Gástricas , Regulação Neoplásica da Expressão Gênica , Humanos , Prognóstico , RNA Longo não Codificante/genética , Reprodutibilidade dos Testes , Neoplasias Gástricas/genética , Neoplasias Gástricas/terapia , Microambiente Tumoral/genética
9.
Biomed Res Int ; 2022: 2747799, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35711526

RESUMO

Long noncoding RNAs (lncRNAs) are closely associated with a variety of tumors, including stomach adenocarcinoma (STAD). However, the role of 5-methylcytosine- (m5C-) related lncRNAs in STAD is still uncertain. This study investigated the value of m5C-related lncRNAs in prognostic evaluation and immunotherapy of STAD. STAD transcriptome sequencing data were downloaded from The Cancer Genome Atlas (TCGA) database, and m5C-related lncRNAs were screened by Pearson correlation analysis. A prognostic m5C-related lncRNA signature (m5CRLSig) associated with STAD was established using univariate and multivariate Cox regression analysis. We constructed a prognostic risk model for STAD with six m5C-related lncRNAs. The receiver operating characteristic (ROC) curve was used to examine the predictive efficacy. Univariate and multifactorial Cox regression analysis and principal component analysis (PCA) validated m5CRLSig as an independent factor of STAD prognosis. The clinicopathological characteristics of the model showed higher risk scores for stages II-IV, grade 3, N1-3, and death status. The calibration curve of a nomogram revealed that the nomogram had an excellent predictive function for survival risk. Furthermore, the expression of six m5C-related lncRNAs in STAD and paracancerous tissues was detected by quantitative real-time PCR (qRT-PCR), which verified the feasibility of the m5CRLSig as a prognostic marker for STAD. m5C-related lncRNAs were linked to multiple immune-associated pathways, according to gene set enrichment analysis (GSEA). CIBERSORT analysis indicated that m5CRLSig was involved in immune cell infiltration. Risk score was associated with immune checkpoint gene expression, immune function scores, and chemotherapeutic drug sensitivity. Therefore, m5CRLSig can efficiently assess the prognosis of STAD patients and can be used as a biological marker for immunotherapy.


Assuntos
Adenocarcinoma , RNA Longo não Codificante , Neoplasias Gástricas , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Adenocarcinoma/terapia , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Regulação Neoplásica da Expressão Gênica , Humanos , Imunoterapia , Prognóstico , RNA Longo não Codificante/genética , RNA Longo não Codificante/metabolismo , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/genética , Neoplasias Gástricas/terapia
10.
Am J Surg ; 224(1 Pt B): 539-545, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35148884

RESUMO

INTRODUCTION: The 2014 Medicaid expansion was intended to improve access to care. We hypothesized that Medicaid expansion would be associated with improved gastric cancer (GC) outcomes. METHODS: We selected patients with a new primary diagnosis of GC from the National Cancer Database. We compared states that expanded Medicaid in 2014 to those that did not. We compared pre-and post-expansion intervals 2012-2013 and 2015-2016. RESULTS: There was an increase in patients diagnosed with stage 0-2 GC from 38% to 41.5% [p < 0.01] in expansion states (ES), but no change at 38.9% in non-expansion states (NES). Uninsured and Medicaid patients diagnosed with stages 0-2 GC increased in ES from 32.4% to 37.8% [p = 0.01] and decreased in NES from 29.7% to 27.3% [p = n.s.]. Uninsured and Medicaid patients receiving treatment rose from 87.0% to 90.3% in ES [p < 0.01] and in NES 83.9%-84.9% [p = n.s.]. Twelve-month survival for ES rose from 68.1% to 70.6% [p = 0.03] and in NES decreased 65.2%-65.1% [p = n.s.]. CONCLUSION: Increased healthcare access may be related to earlier diagnosis and improved outcomes in GC.


Assuntos
Medicaid , Neoplasias Gástricas , Detecção Precoce de Câncer , Humanos , Cobertura do Seguro , Pessoas sem Cobertura de Seguro de Saúde , Patient Protection and Affordable Care Act , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/terapia , Estados Unidos
11.
Front Endocrinol (Lausanne) ; 13: 1076521, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36726460

RESUMO

Background: The significance of nucleotide metabolism and neuroendocrine in cellular immune response and cancer is becoming more well-established. However, the mechanisms underlying nucleotide metabolism and neuroendocrine involvement in stomach adenocarcinoma (STAD) remain unclear. Methods: First, a pan-cancer overview of nucleotide metabolism and neuroendocrine-related genes (NMNGs) was explored through the integration of expression profiles, prognostic values, mutation information, methylation levels, and pathway-regulation relationships. We next extensively assessed variations in prognosis and tumor microenvironment (TME) features across the various modification patterns, based on an extensive analysis of the NMNG modification patterns of 808 STAD samples based on 46 NMNGs. Utilizing principal component analysis methodologies, the NMNGscore was developed to measure NMNG alteration patterns of individual tumors. Results: Pan-cancer analysis shows that NMNGs mostly act as risk genes in multiple cancer types, especially in STAD. Based on the NMNGs we detected two different NMNG modification patterns in STAD. Both patterns showed distinct immune cell infiltration features and biological behavior, with NMNGcluster A exhibiting a worse prognosis and a larger amount of immune infiltration. Differentially expressed genes with prognostic relevance were used to classify the STAD samples into three genomic subgroups. Analysis of survival rates revealed that cluster B genes were associated with longer life expectancy than clusters A and C. Individual STAD patients' NMNG alteration patterns were analyzed by analyzing their NMNGscore signatures. NMNGscore and immune cells showed a statistically significant adverse correlation with each other. Increased longevity, a higher incidence of mutations, and a better response to immunotherapy were associated with patients' NMNG scores. Conclusions: Our findings provide a personalized prediction tool for prognosis and immunotherapy sensitivity in patients, as well as a promising knowledge of nucleotide metabolism and neuroendocrine in STAD.


Assuntos
Adenocarcinoma , Neoplasias Gástricas , Humanos , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Adenocarcinoma/terapia , Imunoterapia , Nucleotídeos , Prognóstico , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/genética , Neoplasias Gástricas/terapia , Microambiente Tumoral/genética
12.
Dis Markers ; 2021: 4251763, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34804261

RESUMO

OBJECTIVE: Due to the molecular heterogeneity of gastric cancer, only minor patients respond to immunotherapeutic schemes. This study is aimed at developing an immune-based gene signature for risk stratification and immunotherapeutic efficacy assessment in gastric cancer. METHODS: An immune-based gene signature was developed in gastric cancer by LASSO method in the training set. The predictive performance was validated in the external datasets. KEGG pathways related to risk scores were assessed by GSEA. Based on multivariate Cox regression analysis, a nomogram was established. Sensitivity to chemotherapy drugs was evaluated between high- and low-risk samples. The relationships of risk scores with infiltration levels of immune cells, stromal scores, immune scores, immune cell subgroups, and overall response to anti-PD-L1 therapy were determined. RESULTS: Our results showed that high risk scores were indicative of undesirable survival outcomes both in the training set (p < 0.0001) and the validation set (p = 0.002). Moreover, this signature could independently predict patients' survival (HR: 2.656 (1.919-3.676) and p < 0.001). Subgroup analysis confirmed the sensitivity of this signature in predicting prognosis (all p < 0.05). Cancer-related pathways were primarily enriched in high-risk samples, such as MAPK and TGF-ß pathways (p < 0.05). By incorporating stage and the risk score, we established a nomogram for predicting one-, three-, and five-year survival probability. Patients with high-risk scores were more sensitive to chemotherapy drugs (p < 0.05). There was heterogeneity in immune cells between high- and low-risk samples (p < 0.05). Samples with progressive disease exhibited the highest risk score, and those with complete response had the lowest risk score (p < 0.05). CONCLUSION: This immune-based gene signature might be representative of a promising prognostic classifier for predicting risk stratification and immunotherapeutic efficacy in gastric cancer, assisting personalized therapy and follow-up plan.


Assuntos
Biomarcadores Tumorais/genética , Regulação Neoplásica da Expressão Gênica , Imunoterapia/mortalidade , Nomogramas , Medição de Risco/métodos , Neoplasias Gástricas/imunologia , Microambiente Tumoral , Idoso , Biomarcadores Tumorais/imunologia , Feminino , Perfilação da Expressão Gênica , Humanos , Masculino , Prognóstico , Neoplasias Gástricas/genética , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/terapia , Taxa de Sobrevida , Transcriptoma
13.
Gastric Cancer ; 24(6): 1355-1364, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34387763

RESUMO

BACKGROUND: This study evaluated the safety, effectiveness, and feasibility of indocyanine green (ICG) tracing in guiding lymph-node (LN) dissection during laparoscopic D2 radical gastrectomy in patients with advanced gastric cancer (AGC) after neoadjuvant chemotherapy (NAC). METHOD: We retrospectively analyzed data on 313 patients with clinical stage of cT1-4N0-3M0 who underwent laparoscopic radical gastrectomy after NAC between February 2010 and October 2020 from two hospitals in China. Grouped according to whether ICG was injected. For the ICG group (n = 102) and non-ICG group (n = 211), 1:1 propensity matching analysis was used. RESULTS: After matching, there was no significant difference in the general clinical pathological data between the two groups (ICG vs. non-ICG: 94 vs. 94). The average number of total LN dissections was significantly higher in the ICG group and lower LN non-compliance rate than in the non-ICG group. Subgroup analysis showed that among patients with LN and tumor did not shrink after NAC, the number of LN dissections was significantly more and LN non-compliance rate was lower in the ICG group than in the non-ICG group. Intraoperative blood loss was significantly lesser in the ICG group than in the non-ICG group, while the recovery and complications of the two groups were similar. CONCLUSION: For patients with poor NAC outcomes, ICG tracing can increase the number of LN dissections during laparoscopic radical gastrectomy, reduce the rate of LN non-compliance, and reduce intraoperative bleeding. Patients with AGC should routinely undergo ICG-guided laparoscopic radical gastrectomy.


Assuntos
Verde de Indocianina/administração & dosagem , Excisão de Linfonodo , Neoplasias Gástricas/terapia , China , Feminino , Gastrectomia , Humanos , Laparoscopia , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Pontuação de Propensão , Estudos Retrospectivos , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/patologia , Análise de Sobrevida
14.
J Health Care Poor Underserved ; 32(3): 1199-1207, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34421025

RESUMO

In the United States, uninsurance remains a major barrier in accessing health care for many citizens and residents. Studies have shown that uninsured patients with many cancers and chronic diseases have worse survival than insured patients. A recent study similarly showed that uninsured patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) have significantly shortened survival. While GEP-NETs are indolent tumors with generally favorable prognosis, comprehensive care involves years of surveillance, imaging, and treatment following resection, all of which carry a large financial burden. In this commentary, we expand on these findings as they relate to insurance-based disparities as well as management and policy implications.


Assuntos
Seguro , Neoplasias Intestinais , Tumores Neuroendócrinos , Neoplasias Pancreáticas , Neoplasias Gástricas , Humanos , Tumores Neuroendócrinos/epidemiologia , Tumores Neuroendócrinos/terapia , Neoplasias Pancreáticas/terapia , Neoplasias Gástricas/terapia , Estados Unidos/epidemiologia
15.
Lima; INEN; jun. 2021.
Não convencional em Espanhol | BRISA/RedTESA | ID: biblio-1282029

RESUMO

INTRODUCIÓN: Se realiza la siguiente revisión rápida: "Adquisición de insumos para la realización de procedimientos en el equipo funcional de gastro - lll stent esofágico y entérico", a solicitud de la dirección de Medicina-departamento de especialidades médicasservicio de gastroenterología. METODOLOGÍA: Se formuló una estrategia de búsqueda de información, que abarcó un periodo de 10 años. Se empleó la base de datos de PubMed y Cochrane. ESTRATEGIA DE BÚSQUEDA DE INFORMACIÓN: a) PREGUNTA CLÍNICA: ¿En pacientes con cáncer esófago o estomago el stent esofágico o stent entérico es mejor que la sonda nasoyeyunal para mejorar la calidad de vida? Términos de Búsqueda: Considerando la pregunta PICO se construyó una estrategia de búsqueda. Sin restricciones en el idioma y publicadas en los últimos 10 años. DISCUSIÓN: Tomando los criterios para un marco de valor de la Health Technology Assessment International (2018)35 para la toma de decisiones y formulación de la recomendación, se describe: La calidad de evidencia es moderada a alta. Se cuenta con una ETS de alta calidad y además con revisiones sistemáticas con meta-análisis. También hay recomendaciones de Guías tanto internacionales como nacionales que emiten una opinión a favor y en contra del uso de los stent entéricos. Las guías internacionales (NCCN y ESMO) son de calidad y de prestigio reconocido. La guía NCCN da una recomendación a favor del uso, pero debe de utilizarse para pacientes con un mal pronóstico de vida pues los stent tienden a perder su eficacia a largo plazo. La guía ESMO da una recomendación a favor de braquiterapia en vez del uso de stent metálico. Las investigaciones han reportado que en pacientes con stent se reanudo prontamente la alimentación oral, se reducido la duración de la estancia hospitalaria y aumentó el tiempo hasta la recurrencia de los síntomas obstructivos. Las revisiones sistemáticas encontradas realizaron adecuada aleatorización, selección de pacientes y seguimiento; no se pudo realizar el cegamiento a los participantes sin embargo creemos que esto no puede afectar los resultados de interés. Los criterios para pacientes que necesitarán stent son: Pacientes con cáncer oncológico que tienen obstrucción maligna por cáncer gástrico estadio IV o esofágico estadio IV con intolerancia oral severa, no tributarios a cirugía, sonda previa de escaso tiempo de duración y alto riesgo de desnutrición. La magnitud del beneficio es moderada, ya que en los ECAs evaluados, el uso de los stents mostró mayores beneficios a corto plazo en pacientes con obstrucciones malignas a nivel esofágicas o gástricas. De ellos, el mejor stent fueron los metálicos autoexpandibles. El impacto económico de esta tecnología para el INEN es incierto, es necesario realizar un análisis de impacto presupuestario para estimar cuantitativamente el gasto sanitario del uso de esta tecnología en nuestra población. Un estudio derivado del ECA SUSTENT36, encontró que los costos iniciales fueron más altos para la gastroyeyunostomía en comparación con la del stent, no encontraron diferencias en los costos de seguimiento, sin embargo, los costos totales por paciente fueron más altos para gastroyeyunostomía en comparación con la del stent. El área usuaria, Gastroenterología médica, señala que el costo de alimentación por sonda gastroyeyunal es mucho mayor que el uso de los stent, y en promedio un 30% se obstruyen y habría que repetir las evaluaciones. Recomendamos que el uso de stent metálicos debe ser reservado solo para pacientes con muy mal pronóstico con obstrucción maligna, en especial a pacientes con cáncer de esófago metastásico localmente irresecable o avanzado. CONCLUSIONES: Alrededor el 62% de personas con cáncer de estómago reciben el diagnóstico cuando el cáncer ya se ha diseminado más allá del lugar donde comenzó. - El cáncer de esófago es la séptima causa más común de muerte por cáncer en los hombres. - En el cáncer de estómago y de esófago, tanto para paliar los síntomas obstructivos como para continuar con la ingesta oral, la colocación de una endoprótesis puede mejorar mucho la calidad de vida del paciente. - Existe evidencia de moderada a alta calidad que demuestra que los stent metálicos son más efectivos en ingesta pronta de alimentos, menor estancia hospitalaria y mejora en la calidad de vida comparado con la sonda nasoyeyunal. - El uso de sonda nasoyeyunal resultó ser más costosa que el stent, en el INEN se estima que el uso de sonda nasoyeyunal aumentaría con el costo de nutrición enteral es mucho mayor que el uso de los stent, y en promedio un 30% se obstruyen. - Los criterios para pacientes que necesitarán stent son: Pacientes con cáncer oncológico que tienen obstrucción maligna por cáncer gástrico estadio IV o esofágico estadio IV con intolerancia oral severa, no tributarios a cirugía, sonda previa de escaso tiempo de duración y alto riesgo de desnutrición. Se estima un requerimiento anual de 150 stent. - Por lo expuesto, la UFETS en consenso con el Comité de ETS, emite opinión favorable para el uso de la tecnología de los stent como opción de tratamiento en pacientes con cáncer de esófago y gástrico con disfagia y/o síndrome pilórico por neoplasia maligna, un pronóstico de vida corto y que cumplan con los criterios mencionados.


Assuntos
Humanos , Neoplasias Gástricas/terapia , Stents/provisão & distribuição , Insumos Farmacêuticos , Avaliação da Tecnologia Biomédica , Avaliação em Saúde/economia
16.
Clin Transl Gastroenterol ; 11(10): e00242, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-33108122

RESUMO

INTRODUCTION: We investigated potential disparities in the diagnosis, treatment, and survival of gastric cancer (GC) patients with and without disabilities. METHODS: We linked Korean National Disability Registry data with the Korean National Health Insurance database and Korean Central Cancer Registry data. This study included a total of 16,849 people with disabilities and 58,872 age- and sex-matched control subjects in whom GC had been diagnosed. RESULTS: When compared to GC patients without disabilities, patients with disabilities tended to be diagnosed at a later stage (localized stage 53.7% vs 59.0% or stage unknown 10.7% vs 6.9%), especially those with severe disabilities (P < 0.001). This was more evident in patients with mental impairment (localized stage 41.7% and stage unknown 15.2%). In addition, not receiving treatment was more common in patients with disabilities than those without disabilities (29.3% vs 27.2%, P < 0.001), and this disparity was more evident in those with severe disabilities (35.4%) and in those with communication (36.9%) and mental (32.3%) impairment. Patients with disabilities were at slightly higher risk of overall mortality as well as GC-specific mortality compared to people without disabilities (adjusted hazard ratio [aHR] = 1.18, 95% confidence interval: 1.14-1.21 and aHR = 1.12, 95% confidence interval: 1.09-1.16, respectively), and these disparities were more pronounced in those with severe disabilities (aHR = 1.62 and 1.51, respectively). DISCUSSION: Patients with disabilities, especially severe disabilities, were diagnosed with GC at a later stage, received less staging evaluation and treatment, and their overall survival rate was slightly worse compared to those without disabilities.


Assuntos
Pessoas com Deficiência/estatística & dados numéricos , Disparidades nos Níveis de Saúde , Disparidades em Assistência à Saúde/estatística & dados numéricos , Neoplasias Gástricas/diagnóstico , Adulto , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Modelos de Riscos Proporcionais , Sistema de Registros/estatística & dados numéricos , República da Coreia/epidemiologia , Estudos Retrospectivos , Medição de Risco/estatística & dados numéricos , Fatores de Risco , Medicina Estatal/estatística & dados numéricos , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/terapia , Taxa de Sobrevida , Adulto Jovem
17.
Zhonghua Liu Xing Bing Xue Za Zhi ; 41(9): 1482-1486, 2020 Sep 10.
Artigo em Chinês | MEDLINE | ID: mdl-33076603

RESUMO

Objective: To investigate the relationship between smoking status and the onset age of stomach cancer patients and estimate the patients' direct medical cost burden of stomach cancer due to smoking in Anhui province. Methods: The information about the primary stomach cancer patients and their direct treatment expenditures in 10 cancer-registered areas in Anhui were collected in 2017. The association between smoking status and the age of onset of stomach cancer patients was analyzed by univariate regression and multivariate logistic regression models. The median and smoking-attributed risk method was used to describe the direct treatment expenditure of stomach cancer patients in Anhui due to smoking. Results: A total of 736 patients with stomach cancer were analyzed in this study. Univariate regression analysis showed that rural household registration (t=2.091, P=0.037), smoking (t=-2.357, P=0.001 9) and alcohol consumption (t=-2.036, P=0.042) were related to the age of onset of stomach cancer. After adjusting for gender, alcohol consumption, body mass index and household registration type, the risk of early stomach cancer in people who quitted smoking cessation was lower than that in smokers (OR=0.36, 95%CI: 0.17-0.75). The total direct medical cost burden of 736 newly diagnosed stomach cancer patients was 6.939 6 million RMB. The direct medical expenditure in stomach cancer patients who had smoking behavior was higher than that in stomach cancer patients who quitted smoking and never smoked. Conclusions: Smoking is one of the risk factors for the earlier onset of stomach cancer in Anhui. It is necessary to strengthen tobacco control to reduce the economic burden of patients with stomach cancer.


Assuntos
Fumar , Neoplasias Gástricas , Idade de Início , China/epidemiologia , Gastos em Saúde , Humanos , Fumar/epidemiologia , Neoplasias Gástricas/economia , Neoplasias Gástricas/epidemiologia , Neoplasias Gástricas/terapia
18.
Cancer Med ; 9(23): 8940-8949, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33047873

RESUMO

BACKGROUND: Positive peritoneal cytology (PCY) indicates metastasis (M1) in gastric cancer (GC) patients; both the American and Chinese guidelines recommend laparoscopic peritoneal lavage (LPL) for cytology. However, relatively high costs impair the widespread use of LPL in some resource-limited regions in China, and the cost-effectiveness of PCY testing remains unclear. Therefore, we performed a decision analysis to evaluate the cost-effectiveness of PCY testing by comparing the guideline-recommended intraoperative LPL, a newly proposed preoperative percutaneous peritoneal lavage (PPL), and a third strategy of exploratory laparotomy with no cytology testing (ELNC) among GC patients. METHODS: We developed a decision-analytic Markov model of the aforementioned three strategies for a hypothetical cohort of GC patients with curative intent after initial imaging, from the perspective of Chinese society. We estimated costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) as primary outcomes; we also conducted one-way and probabilistic sensitivity analyses to investigate the model's robustness. RESULTS: We found that ELNC was dominated (i.e., more expensive and less effective) by PPL and LPL. LPL was the most cost-effective method with an ICER of US$17,200/QALY compared to PPL, which was below the Chinese willingness-to-pay (WTP) threshold of US$29,313 per QALY gained. In sensitivity analyses, PPL was more likely to be cost-effective with a lower WTP threshold. CONCLUSIONS: Cytology testing through either LPL or PPL was less expensive and more effective than ELNC among GC patients. Moreover, LPL was the most cost-effective modality at the current WTP threshold, while PPL could potentially be cost-effective in lower-income areas.


Assuntos
Citodiagnóstico , Técnicas de Apoio para a Decisão , Lavagem Peritoneal , Neoplasias Peritoneais/secundário , Peritônio/patologia , Neoplasias Gástricas/patologia , Idoso , China , Tomada de Decisão Clínica , Análise Custo-Benefício , Citodiagnóstico/economia , Árvores de Decisões , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Cadeias de Markov , Estadiamento de Neoplasias , Lavagem Peritoneal/economia , Neoplasias Peritoneais/economia , Neoplasias Peritoneais/terapia , Valor Preditivo dos Testes , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Reprodutibilidade dos Testes , Neoplasias Gástricas/economia , Neoplasias Gástricas/terapia , Resultado do Tratamento
19.
Cancer Prev Res (Phila) ; 13(9): 773-782, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32561562

RESUMO

Gastric carcinoma (GC) disproportionately affects Asian Americans. We examined whether history of upper gastrointestinal (GI) endoscopy was associated with lower stage at GC diagnosis among Asian Americans and whether origin of providers influenced referral for endoscopy. We employed Surveillance Epidemiology and End Results-Medicare data on Asian Americans diagnosed with GC in 2004-2013 (n = 1,554). Stage distribution, GI conditions at diagnosis, and history of endoscopy were compared between Asian ethnic groups. Multivariate logistic regression adjusting for age, sex, poverty level, tumor location, and histology was used to examine the association of ethnicity and endoscopic history with stage I disease at diagnosis of GC. Koreans were more likely to be diagnosed with stage I, T1a GC and have prior history of endoscopy, compared with other Asian ethnicities (24% vs. 8% for stage I, T1a; 40% vs. 15% for endoscopy). Patients with primary care providers of concordant ethnic origin were more likely to have history of endoscopy. Asian American patients with GC with history of endoscopy were more likely to be diagnosed with GC at stage I disease (adjusted OR, 3.07; 95% confidence interval, 2.34-4.02). Compared with other Asian Americans, Koreans were diagnosed with GC at earlier stages owing to common history of endoscopy, which was more often undergone by patients with primary care providers of concordant ethnic origin. Overall, upper GI endoscopy was associated with early detection of GC in Asian Americans. Novelty and Impact. It is well-established that Asian Americans in the United States are disproportionately affected by gastric cancer. In our study we found that Asian American patients treated by physicians of similar ethnic background are more likely to undergo upper GI endoscopy in the United States, leading to early detection of gastric cancer and longer survival. Given this, targeted endoscopic screening in Asian Americans should be considered for early detection of GC.


Assuntos
Carcinoma/mortalidade , Gastroscopia/estatística & dados numéricos , Disparidades em Assistência à Saúde/estatística & dados numéricos , Programas de Rastreamento/estatística & dados numéricos , Neoplasias Gástricas/mortalidade , Idoso , Idoso de 80 Anos ou mais , Asiático/estatística & dados numéricos , Carcinoma/diagnóstico , Carcinoma/economia , Feminino , Disparidades em Assistência à Saúde/economia , Humanos , Masculino , Programas de Rastreamento/economia , Medicare/economia , Medicare/estatística & dados numéricos , Estadiamento de Neoplasias , Médicos de Atenção Primária/estatística & dados numéricos , Pobreza/estatística & dados numéricos , Encaminhamento e Consulta/economia , Encaminhamento e Consulta/estatística & dados numéricos , Programa de SEER/estatística & dados numéricos , Estômago/diagnóstico por imagem , Estômago/patologia , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/economia , Neoplasias Gástricas/terapia , Estados Unidos/epidemiologia
20.
J Cancer Res Ther ; 16(1): 102-104, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32362617

RESUMO

CONTEXT: Health-related quality of life (HRQOL) assessment plays an important role in the decision-making process in oncology. AIMS: The aim of the study was to translate European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) OES18 and OG25 in Punjabi language for HRQOL assessment of patients diagnosed with esophagus and esophagogastric malignancies. SUBJECTS AND METHODS: The EORTC translation guidelines were duly followed to translate QLQ-OES18 and OG25 into Punjabi language. Each set of questionnaire was independently translated by two forward translators, followed by backward translation of the reconciled version by two independent translators. The final version was submitted to the EORTC Translation Team and served to the patients for the pilot testing. RESULTS: The questionnaire was administered to ten patients each of esophagus and esophagogastric malignancies who were evaluated and treated at our hospital. Every patient underwent an interview to check if any of the questions was difficult, uncomfortable, or upsetting to answer. Their concerns were recorded as per the template provided by the EORTC team and due changes done if required. CONCLUSIONS: The EORTC QLQ-OES18 and OG25 questionnaire has been translated to Punjabi language and subsequently approved for usage.


Assuntos
Neoplasias Esofágicas/terapia , Etnicidade/estatística & dados numéricos , Psicometria/métodos , Qualidade de Vida/psicologia , Neoplasias Gástricas/terapia , Inquéritos e Questionários/normas , Neoplasias Esofágicas/psicologia , Humanos , Índia , Idioma , Reprodutibilidade dos Testes , Neoplasias Gástricas/psicologia , Traduções
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA